Newsletter | October 20, 2026

10.20.26 -- Could Today's Development Decisions Create Tomorrow's Risks?

The Delicate Dance: When Phase-Appropriate Decisions Carry More Risk

Phase-appropriate development helps drug developers balance speed, risk, and investment, but early decisions can create challenges later. Learn where a longer-term perspective can prevent today’s choices from becoming tomorrow’s manufacturing limitations.

 

Full IND Program: Exceeding Requirements For Submission

Follow a compound through a full IND development cycle, from modifications to the synthetic route through formulation development and API manufacturing, and see how each stage supports submission.

 

End-To-End Development And Manufacturing: Small Volume Commercial Drug Products

Sponsors spend considerable time and resources on process development and validation to create a launch-ready manufacturing process, which might require refinement. More often, significant process refinement is needed when adding CDMOs in preparation for process validation and commercial launch.

 

Route Development: Designing Synthesis For GMP Production

The successful transition from initial synthesis of an API to a kilogram-scale route requires expert analysis and design, and a balance of economic, regulatory, and time constraints.

 

VIDEO FEATURE

Ask Us Anything: Anmaris Torres On The First Steps In Process Transfer

Anmaris Torres, Process Engineering Team Leader, on why a process transfer starts with a conversation across departments to figure out how to cut cycle time before commercial production begins.

 

SOLUTIONS

Our Science-Forward Approach To API Development, Manufacturing

Cambrex's highly skilled team of chemists and process engineers, combined with a science-driven project management approach, ensures seamless execution at every stage.